Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 359

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 8
Chunk 359
---
31)$58,823 U.S. treasury securities46,231 80 (2)46,309 Corporate debt securities43,634 49 (14)43,669 U.S. government agency securities40,013 60 (2)40,071 Totals$208,365 $245 $(49)$208,561 The following table presents available-for-sale securities by contractual maturity date as of June 30, 2025 (in thousands):June 30, 2025Amortized CostEstimated Fair ValueDue in one year or less$157,218 $157,228 Due after one year14,655 14,683 Total$171,873 $171,911 As of June 30, 2025, fifty-one of the Company's marketable securities with a fair market value of $70.7 million were in an immaterial aggregate gross unrealized loss position; these fifty-one marketable securities have all been in a gross unrealized loss position for less than one year. Based on a review of these marketable securities, the Company believes none of the unrealized loss is the result of a credit loss as of June 30, 2025, because the Company does not intend to sell these securities, and it is not more-likely-than-not that the Company will be required to sell these securities before the recovery of their amortized cost basis. Refer to Note 2 for further discussion on the Company's evaluation of unrealized losses on available-for-sale securities. Accrued interest receivable on marketable securities was $1.3 million and $1.1 million at June 30, 2025 and December 31, 2024, respectively, and was recorded within prepaid expenses and other current assets in the condensed consolidated balance sheets. We did not write off any accrued interest receivables for the six months ended June 30, 2025 and 2024.The Company did not transfer any assets measured at fair value on a recurring basis between levels during the six months ended June 30, 2025 and 2024.

16

The following table presents activity for the preferred stock warrants liability during the six months ended June 30, 2024 (in thousands):Preferred Stock Warrants LiabilityBalance at December 31, 2023$871 Change in fair value1,047 Conversion of preferred stock warrants liability to equity(1,918)Balance at June 30, 2024